FDA clears Cordis' Empira catheters

The FDA has cleared Cordis' EMPIRA and EMPIRA NC RX PTCA dilatation catheters for the treatment of coronary artery disease. The U.S. launch is expected early next year. "The EMPIRA Balloon Catheters offer our most advanced technology designed to treat challenging coronary artery disease," explained Campbell Rogers, Cordis chief scientific officer, global head R&D. "Cordis worked closely with our physician-customers and incorporated their feedback into the design of these next generation devices." Cordis release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.